论文部分内容阅读
目的比较甘舒霖30R与口服降糖药治疗糖尿病肾病的效果及低血糖风险。方法64例Ⅱ型糖尿病患者随机分为甘舒霖30R组和口服降糖药组,进行为期4周的观察。比较空腹及餐后2h血糖、尿微量白蛋白、糖化血红蛋白(HbAlc)及低血糖事件的差异。结果甘舒霖30R组和口服降糖药组治疗后,血糖均较前明显下降,4周后甘舒霖30R组餐后2h血糖低于口服降糖药组,差异有统计学意义(P<0.05),HbAlc水平无明显变化,甘舒霖组低血糖发生次数高于口服降糖药组,但差异无统计学意义(P>0.05),尿微量白蛋白明显下降,两组相比,甘舒霖30R组优于口服降糖药组(P<0.05)。结论Ⅱ型糖尿病肾病患者,甘舒霖30R对降低血糖、减少尿微量蛋白更有效,低血糖风险与口服降糖药相同,是糖尿病肾病患者较好治疗途径。
Objective To compare the effects of Ganshulin 30R and oral hypoglycemic agents on diabetic nephropathy and the risk of hypoglycemia. Methods Sixty-four patients with type 2 diabetes were randomly divided into Gansuolin 30R group and oral hypoglycemic group for 4 weeks. Fasting and postprandial 2h blood glucose, urine microalbumin, glycosylated hemoglobin (HbAlc) and hypoglycemic events differences. Results Gansu Lin 30R group and oral hypoglycemic group after treatment, the blood glucose were significantly lower than before, after 4 weeks Gansu Lin 30R group 2h postprandial blood glucose lower than the oral hypoglycemic group, the difference was statistically significant (P <0.05), HbAlc The level of hypoglycemia in Gansu Lulin group was higher than that in oral hypoglycemic group, but the difference was not statistically significant (P> 0.05), urine microalbumin significantly decreased compared with the two groups, Gan Shu Lin 30R group was better than oral administration Sugar group (P <0.05). Conclusions In patients with type 2 diabetic nephropathy, Ganshulin 30R is more effective in lowering blood glucose and reducing microalbuminuria. The risk of hypoglycemia is the same as that of oral hypoglycemic agents. It is a good treatment for patients with diabetic nephropathy.